Supplemental figure 1

Budget impact analysis – retrospective models for assessing the benefits of biosimilars reimbursement. Both models are based on real drug utilization and the final drug price for hospitals, reflecting the true cost of the public payer.

- **Estimated savings**
  - More accessible
  - Current drug utilization
  - Final price of drugs for hospitals resulting from the tender procedures
  - Retrospective analysis
  - Current vs estimated value of reimbursement based on current vs reference drug price – difference between the estimated and current value (reference price – price of reference drug from the year preceding the coverage of the first biosimilar)
  - The more patients treated, the greater savings, always present if the cost of the therapy is lower
  - Does not provide information on the potential use of the treatment costs reduction to treat more patients, i.e. increasing access

- **Real-life savings**
  - More difficult to access
  - Current value of reimbursement vs value in the reference year – difference between the reference year and the analyzed year (reference year – generally the year preceding the coverage of the first biosimilar)
  - The more patients treated, the less savings may not occur if savings are fully reinvested in the treatment of a correspondingly larger number of patients
  - Allows to determine whether the reduction of the cost of therapy is related to the increased availability, i.e. to what extent it is reinvested in the reimbursement of the analyzed drugs

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance upon the supplemental material (m) which has been supplied by the author(s).